ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Accepts NDA for First Potential Treatment for Fibrodysplasia Ossificans Progressiva americanpharmaceuticalreview
June 04, 2021Ipsen announced that its New Drug Application (NDA) for palovarotene, an oral, investigational, selective RARγ agonist for the prevention of heterotopic ossification (new bone formation) as a potential treatment option for people living with the ... -
Regeneron Announces Phase 2 Results for Garetosmab americanpharmaceuticalreview
January 14, 2020Regeneron Pharmaceuticals announced results from LUMINA-1, a 44-patient, Phase 2, double-blind placebo-controlled trial evaluating garetosmab (REGN2477) in patients with fibrodysplasia ossificans progressiva (FOP).
Pharma Sources Insight January 2025
